3 Personal Products Stocks to Buy Now

NATR, NUS, MED improve in weekly rankings

   
3 Personal Products Stocks to Buy Now

Three Personal Products stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).

Nature’s Sunshine Products (NASDAQ:NATR) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. Nature’s Sunshine Products manufactures and distributes nutritional and personal care products. In Portfolio Grader’s specific subcategories of Earnings Momentum, Earnings Revisions, Equity, Cash Flow, and Margin Growth, NATR also gets A’s. For more information, get Portfolio Grader’s complete analysis of NATR stock.

Nu Skin Enterprises (NYSE:NUS) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Nu Skin Enterprises distributes premium quality personal care products and nutritional supplements. The stock price has risen 6.4% over the past month, better than the 2.2% increase the S&P 500 has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of NUS stock.

Medifast (NYSE:MED) boosts its rating from a C to a B this week. Medifast combines physician-supervised weight loss programs with nutritional supplements and multidisciplinary patient education programs. Wall Street has pushed the stock higher by 28.9% over the past month. For more information, get Portfolio Grader’s complete analysis of MED stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, http://investorplace.com/2012/07/3-personal-products-stocks-to-buy-now-natr-nus-med/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.